First human tests of smoking vaccine
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The first human trials are to begin of an anti-smoking vaccine, the British company responsible for its development said yesterday.
The Cambridge-based biotechnology company Xenova said its vaccine, TA-NIC – which is being developed for the treatment of nicotine addiction – had been accepted for phase 1 clinical trials. It will be tested on 60 smokers and non-smokers and works by "mopping up" nicotine before it reaches the brain and triggers addiction responses.
Xenova's medical director, John St Clair Roberts, said: "This is the first time an anti-smoking vaccine has gone under clinical trials. We are trying to keep nicotine out of the brain unlike other nicotine replacement therapies." He said the vaccine, which will be injected, works because nicotine molecules are so small they are not recognised by the immune system. It would alter the immune system so it would recognise nicotine and produce antibodies.
David Oxlade, Xenova's chief executive, said: ""Although at an early stage of development, if TA-NIC can be of assistance it could have an important contribution to make in reducing the burdens that smoking imposes."
Clive Bates, of the anti-smoking pressure group ASH, said: "A nicotine vaccine would be a profound development, which would effectively become one of the most important medicines in the response to cancer, lung and heart disease."
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments